Open in interactive viewer → charts, metric popovers & call review

Absci Is Asking the Market to Grade 13 Weeks of Hair

A 25% drawdown into a December binary, an efficacy narrative quietly rewritten around vellus hairs, and a commercial build-out that has arrived before the data has
ABSI · Earnings Call · 2026-11-12

The Setup: Sold Off Into Its Own Catalyst

Absci is a $1.57 billion equity with one thing that matters in the next sixty days: an interim 13-week proof-of-concept readout in pattern hair loss due next month, followed by full 26-week data in early 2027. That is not a new promise — it has been the plan for at least three calls — but the tape around this print is doing something uncomfortable. The stock is off 20.3% over the last 90 trading days, including a 28% slide in the final nine sessions into the November 12 report, leaving it 24.5% below its October 29 high of $12.10. Against a 2021 IPO-era peak of $30.29, the name sits down roughly 58% for its public life. So the sequence is: a binary-outcome biotech, roughly two-thirds cycled from its high, de-risking aggressively right as the catalyst window opens. That is a different story than a company guiding up into strength. Management did not address the price action; the transcript is uniformly forward-looking and cheerful. But the mechanics of the quarter are worth noting — a roughly $27 million sequential drawdown in cash, R&D up 11% year over year, and a story that now depends almost entirely on what a machine counting hair follicles in a photograph decides to report in December.

The Language Changed, Even as Management Says It Didn't

Here is the most interesting thing in this dossier. Absci's keyword fingerprint moved sharply between the September quarter and this one. In 20263 the top themes were pattern hair loss, then receptor occupancy at number two, then androgen receptor biology. In 20264 the ranking is entirely different: hair count first, non vellus second, vellus hair third, with total hair rounding out the top five. Receptor occupancy has fallen out of the conversation almost entirely. That matters because receptor occupancy *was* the argument. For two straight quarters management's central differentiator against Hope Medicine's HMI-115 was pharmacological: sustained blockade above 90% without oscillation, on a 65-day half-life versus a two-week one. On this call, that entire thesis surfaced only as a follow-up from a BTIG analyst who had to ask her question twice because the CMO did not follow it, and was greeted with “I do not think we have commented on the actual sequences” — Ransi Somaratne FACC, Chief Medical Officer · 2026-11-12 before the CEO stepped back in to restate the half-life point. Compare that to August, when Sean McClain volunteered the whole model unprompted: “If you look at HMI-115, the once-every-2-weeks, dosing at 240 milligrams You saw this oscillation that occurred... between 60-70% receptor, occupancy.” — Sean McClain, CEO · 2026-08-11 The differentiation case has not been withdrawn — but it has been demoted from lead argument to defensive answer. In its place: a broader, fuzzier efficacy definition. Vamil Divan of Guggenheim asked directly whether the new emphasis on total hair — including vellus hairs under the 30-micron cutoff — represented a shift. McClain's answer was flat: “So first off, on the total hair count looking at both vellus and non-vellus, that is definitely not a change.” — Sean McClain, Chief Executive Officer · 2026-11-12 Technically true, since total hair was disclosed as a planned endpoint in August. But the emphasis has plainly moved, and the reason is not hard to infer. When the readout is 13 weeks and the conventional regulatory metric is a 26-week endpoint, you want as many ways to be right as possible. The CMO's framing gave it away: “this definition of vellus versus non-vellus is kind of a numerical cutoff. it is not really a biological cutoff.” — Ransi Somaratne FACC, Chief Medical Officer · 2026-11-12 One more disappearance worth flagging: ABS 202, the second prolactin asset that topped this company's keyword ranking in 20262, generated not a single mention on the call. It is now among the sharpest keyword decliners. The pipeline has been narrowed to one molecule and, arguably, one readout.

More recently been focusing a little bit more on the total hair count that you will be disclosing, not just the sort of non-vellus hair count... maybe you can give a little more color on sort of if that is a shift.

Vamil Divan, Analyst · 2026-11-12

The Commercial Machine Arrives Before the Proof

Absci hired its first chief commercial officer, Gary Mule, and spent a meaningful slice of the prepared remarks on distribution economics: a $25 billion U.S. total addressable market for the hair-loss indication on a target product profile of 30 to 35 additional hairs per square centimeter, and more than $4 billion in peak sales for endometriosis. Consumer research and KOL surveys were invoked repeatedly. That is a direct-to-consumer build-out, and it is being funded ahead of any human efficacy data — a real strategic commitment, and also a real cost that will not show up as a Phase 3 line item. The commercial framing also reveals where the bar actually sits. Zachariah Jonasson was explicit that the benchmark is “an effect size similar to high dose oral so think of something in the 30 to 35 hairs per square centimeter range and target area hair count” — Zachariah Jonasson, Chief Commercial Officer · 2026-11-12 — which has been the consistent target since March, when the number was quoted as 35 to 40. The bar has not moved up. Meanwhile the female cohort enrollment has begun at 300mg and 1,200mg, open-label with no placebo arm, chosen as a dose bracket rather than as a response to male data: “it is not based on what we have seen in the male cohorts.” — Ransi Somaratne FACC, Chief Medical Officer · 2026-11-12 That is disclosed as exploratory, but it also means the female opportunity will not be adjudicated by this dataset. The 13-week cut itself will be partial: essentially the full 300mg cohort, most of the 600mg, and a peek at 1,200mg, with safety presented pooled by dose group rather than drug-versus-placebo. No unblinding. No pigmentation data until 26 weeks. So the December event is a mechanism smell test, not an efficacy verdict — consistent with what management has said for two quarters, including in May: “The 13 weeks is really a directional readout. We want to see hair growth, and the 26-week is where we expect to see the oral minoxidil hairs-per-cm² effect.” — Sean McClain, CEO or Senior Executive · 2026-05-07

The Clock, the Cash, and the Quiet Slippage

What has genuinely changed is the calendar. In November 2025, the CFO put the interim readout in the “early part of the second half of next year” — Zachariah Jonasson, Chief Financial Officer · 2025-11-12 — i.e., roughly mid-2026. It is now December 2026, with full data pushed to early 2027. The endometriosis Phase 2, once framed for "later this year," is now guided to ABS 201 program initiation in mid-2027, a shift an H.C. Wainwright analyst raised directly and which drew only a promise of more clarity next year. Financially, the runway is not the issue. Cash and securities stood at $173.7 million at September 30, down from $201.1 million at June 30 — with management guiding the balance into the second half of 2028. Net income losses have been remarkably stable in the low-to-mid $30 millions per quarter for six straight quarters, and stock-based compensation is running around $5 million a quarter, so the burn is boring in the best sense. Effective net cash of roughly $202 million at the last reported quarter, against a cash runway near 7.3 quarters, frames the real constraint. If the December signal is soft and the 26-week readout slips again, the financing window closes before the answer arrives. And research and development at $23.6 million, up 11% year over year says the clinical spend is just beginning. The story in one line: Absci has one molecule, one dataset five weeks away, a stock already 25% off its recent high, and a management team that has begun selling the commercial dream in the same breath it stopped leading with the pharmacological proof. December will tell you whether the follicle is awake. What it will not tell you — because the company has structured it not to — is whether the hair is.